Skip to content
Clinical Trials – home

Servei De Salut De Les Illes Balears

Research site

Spain Carretera Valldemossa 79, 07120 Palma, Spain

  • 118 trials recruiting
  • Non-small cell lung cancer · Breast cancer · Chronic obstructive pulmonary disease
  • Adults and children

About Specializations

Servei De Salut De Les Illes Balears in Palma, Spain specialises in clinical trials of conditions such as Non-small cell lung cancer, Breast cancer, Chronic obstructive pulmonary disease, Acute myeloid leukaemia, and other specialisations. This site conducts important research.

Main research areas of the site

Respiratory Medicine and Lung Disease

The Servicio de Neumología at Servei De Salut De Les Illes Balears is highly active in respiratory tract diseases, with studies focused on asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, pulmonary arterial hypertension, and other complex lung conditions. These trials are mainly designed to test new treatments, improve symptom control, and better understand how to reduce exacerbations and slow disease progression.

  • Asthma, including eosinophilic and difficult-to-control forms
  • Chronic obstructive pulmonary disease and chronic bronchitis
  • Idiopathic pulmonary fibrosis and progressive pulmonary fibrosis
  • Pulmonary arterial hypertension and pulmonary hypertension linked to lung disease

Several studies also address severe pneumonia, bronchiectasis, and allergic airway disease, reflecting a strong focus on improving long-term respiratory care and treatment effectiveness in Palma.

Oncology and Hematologic Malignancies

This site conducts extensive research in neoplasms and hemic and lymphatic diseases, especially across breast cancer, non-small cell lung cancer, multiple myeloma, lymphoma, and leukemia. The trials commonly aim to evaluate newer therapies, compare treatment strategies, and improve outcomes for patients with advanced, relapsed, or high-risk cancers.

  • Breast cancer, including HER2-positive, HR-positive, and triple-negative disease
  • Non-small cell lung cancer, including KRAS-mutant and metastatic disease
  • Multiple myeloma and myelodysplastic syndromes
  • Acute and chronic leukemias, plus lymphoma subtypes

Research at Servei De Salut De Les Illes Balears also includes studies in ovarian, endometrial, prostate, renal, and colorectal cancers, showing a broad commitment to advancing cancer treatment across multiple tumor types.

Cardiovascular and Vascular Research

Clinical trials in cardiovascular diseases at this hospital site focus on prevention, risk reduction, and better management of serious vascular conditions. Main areas include atherosclerotic cardiovascular disease, coronary artery disease, stroke, pulmonary embolism, and pulmonary arterial hypertension, with the goal of improving outcomes and reducing future events.

  • Atherosclerotic cardiovascular disease and elevated lipoprotein(a)
  • Acute ischemic stroke and transient ischemic attack
  • Coronary disease and heart-related complications
  • Pulmonary vascular disorders, including pulmonary arterial hypertension

Some studies also explore inherited heart conditions such as dilated cardiomyopathy, highlighting interest in early intervention and prevention before symptoms become severe.

Immunology, Inflammatory, and Dermatology Studies

Research in immune system diseases and skin and connective tissue diseases includes trials in atopic dermatitis, plaque psoriasis, hidradenitis suppurativa, systemic sclerosis-associated interstitial lung disease, and lupus nephritis. These studies are generally aimed at testing new options that may better control inflammation, reduce flares, and improve quality of life.

  • Atopic dermatitis and psoriasis
  • Hidradenitis suppurativa and other chronic inflammatory skin disorders
  • Autoimmune and inflammatory conditions such as lupus nephritis and systemic sclerosis
  • Immune-mediated lung and kidney complications

The site’s work in these areas reflects a strong interest in therapies that can provide more durable control of chronic immune-driven disease.

Metabolic, Endocrine, and Kidney Disease Research

Trials in nutritional and metabolic diseases, hormonal diseases, and reproductive and urinary physiological phenomena cover diabetes, obesity, metabolic dysfunction-associated steatotic liver disease, chronic kidney disease, and glomerular disorders. The main purpose is to evaluate new treatments and better strategies for preventing complications in patients with long-term metabolic or renal illness.

  • Type 2 diabetes, obesity, and related cardiovascular risk
  • Chronic kidney disease, albuminuria, and end-stage kidney disease
  • IgA nephropathy, lupus nephritis, and focal segmental glomerulosclerosis
  • Fatty liver disease and other metabolic complications

These studies often focus on preserving organ function, reducing inflammation, and improving day-to-day disease control for patients with overlapping metabolic and kidney conditions.

Infectious Diseases and Antimicrobial Research

The site also supports trials in virus diseases, bacterial infections, and related infectious conditions, including HIV, hepatitis B, latent tuberculosis infection, and bloodstream or device-related infections. The research is aimed at improving prevention, treatment effectiveness, and long-term infection control.

  • HIV and HIV-1 infection
  • Chronic hepatitis B
  • Latent tuberculosis infection in high-risk patients
  • Bacteremia and other serious bacterial infections

There is also interest in preventing infection-related complications in vulnerable groups, including patients with kidney disease, cancer, or implanted medical devices.

Neurology, Psychiatry, and Rare Disease Studies

Clinical research at this site spans nervous system diseases and mental disorders, with studies in stroke, multiple sclerosis, Huntington disease, Alzheimer’s-related agitation, depression, and generalized anxiety disorder. The goal is to improve treatment response, symptom relief, and overall neurological or psychological functioning.

  • Acute stroke and brain injury-related conditions
  • Multiple sclerosis and other chronic neurologic disorders
  • Depression, bipolar depression, and anxiety disorders
  • Rare neurodegenerative and developmental conditions

These studies add breadth to the site’s portfolio by addressing both common and uncommon disorders that can significantly affect quality of life.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Carretera Valldemossa 7907120 PalmaSpain
Recruiting now
118 trials
Conditions studied
190

More sites in PalmaSpain

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

303 clinical trials

Hidradenitis

Recruiting

Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Asthma

Recruiting

Study to evaluate the long-term safety and effectiveness of lunsekimig in adults with moderate to severe asthma

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Anastrozole
  • Sponsor:Unicancer

Bronchiectasis

Recruiting

Study of BI 1291583 tablets taken once daily for 76 weeks in adults with bronchiectasis

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:BI 1291583
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study on the Effects of Baxdrostat and Dapagliflozin in Adults with Chronic Kidney Disease and High Blood Pressure

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Breast cancer+1

Recruiting

Study on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Sargramostim
  • Sponsor:Greenwich LifeSciences Inc.

Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Clazakizumab
  • Sponsor:CSL Behring LLC

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Eli Lilly & Co.

Influenza+1

Recruiting

Efficacy and safety of the investigational mRNA influenza vaccine gskvx000000077430 (drug combination) in adults ≥ 65 years

Registered drugNo placebo
Countries:SpainSpain
  • Participants:65+ years · Healthy volunteers
  • Substances:INFLUENZA A VIRUS, A/CROATIA/10136RV/2023 (H3N2) LIKE STRAIN X-425A, INACTIVATED
  • Sponsor:GlaxoSmithKline Biologicals

Rinatabart Sesutecan with or without bevacizumab versus standard platinum‑based chemotherapy drug combination in patients with recurrent platinum‑sensitive ovarian cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Neoplasm

Recruiting

Long‑term Safety of Adagrasib with Drug Combination in Adults with Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Breast cancer+1

Recruiting

Evaluation of zongertinib, fulvestrant and goserelin acetate in patients with HR‑positive HER2‑negative advanced breast cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Medica Scientia Innovation Research S.L.
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.